Skip to Main Content

Author Details

Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
2000
159
43
PMIDPaper TitleJournal TitlePublished Year
36327154Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification.Blood2023
37756525Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.Blood2023
37715270Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.Trials2023
38066853Improving long-term outcomes with intensive induction chemotherapy for patients with AML.Hematology Am Soc Hematol Educ Program2023
37850414Steady-state versus chemotherapy-based hematopoietic cell mobilization after anti-CD38-based induction therapy in newly diagnosed multiple myeloma.Transfusion2023
37833543Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia.Leukemia2023
37783805Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial.Nat Cancer2023
37542108Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.Br J Cancer2023
37679502Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia - implications for the European LeukemiaNet risk classification.Leukemia2023
37971761Gemtuzumab ozogamicin in AML: the next chapter.Blood2023
35708137Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning.Haematologica2023
37086447A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.Hematol Oncol2023
37084345Management of Pathological Thoracolumbar Vertebral Fractures in Patients With Multiple Myeloma: Multidisciplinary Recommendations.Global Spine J2023
37236968UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome.Blood Cancer J2023
37198246Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles.Commun Med (Lond)2023
36480300Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.JCI Insight2023
36815361Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia.Haematologica2023
36693840Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome.Blood Cancer J2023
36779591Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and <i>KIT</i> and/or <i>FLT3</i>- ITD mutations: results of the SAL MIDOKIT trial.Haematologica2023
36689727Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.Blood Adv2023
36508705Overlapping features of therapy-related and de novo NPM1-mutated AML.Blood2023
36757706Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA Oncol2023
36453648Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs.Blood Adv2023
36411356Isocitrate dehydrogenase 1 mutation drives leukemogenesis by PDGFRA activation due to insulator disruption in acute myeloid leukemia (AML).Leukemia2023
36167894Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.J Cancer Res Clin Oncol2023
34320176CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.Blood2022
35797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022
35468621Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.Blood Adv2022
35857899Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.Blood2022
35637252Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.Blood Cancer J2022
35821023A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.Blood Cancer J2022
35562747Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations.J Hematol Oncol2022
35387132Point Mutations in the <i>FLT3</i>-ITD Region Are Rare but Recurrent Alterations in Adult AML and Associated With Concomitant <i>KMT2A</i>-PTD.Front Oncol2022
35851154Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia.Leukemia2022
35413116Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial.Blood Adv2022
36064577Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.J Hematol Oncol2022
36258922Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies.Hemasphere2022
36050938Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation.Ther Adv Hematol2022
35320339Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.Blood Adv2022
34983928Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.Nat Commun2022
35245447The proteogenomic subtypes of acute myeloid leukemia.Cancer Cell2022
35210852Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of Relapse.Cancer Manag Res2022
34794176Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Blood Adv2022
34497326Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears.Leukemia2022
34669022Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.Cancer Chemother Pharmacol2022
34775483Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.Leukemia2022
34348451Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.Haematologica2022
32561840A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.Leukemia2021
33603142Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial.Leukemia2021
33926021Loss-of-Function Mutations of <i>BCOR</i> Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia.Cancers (Basel)2021
  • 1 - 50 of 159

Recommended Authors

Lohith Gowda
Yale Cancer Center and Yale School of Medicine
Career Start Year 2018
Number of shared co-authors 1
Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 6
Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Career Start Year 2015
Number of shared co-authors 11
Jennifer N Saultz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 4
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 8
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 4
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 12
Prapti Patel
The University of Texas Southwestern Medical Center
Career Start Year 2009
Number of shared co-authors 10
Patricia Kropf
Novant Health Cancer Institute - Elizabeth
Career Start Year 2009
Number of shared co-authors 9
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 4
Uma Borate
The Ohio State University
Career Start Year 2008
Number of shared co-authors 11
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 9
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 12
Daniel A Pollyea
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 17
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 6
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 6
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 14
Ivan Pasic
Princess Margaret Cancer Centre
Career Start Year 2001
Number of shared co-authors 0
Susan Geyer
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2001
Number of shared co-authors 7
Todd A Alonzo
Keck School of Medicine, University of Southern California
Career Start Year 1999
Number of shared co-authors 4
Guillermo Garcia-Manero
MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 24
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Career Start Year 1995
Number of shared co-authors 6
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 12
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 2
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 17
Peter Westervelt
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 10
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 15
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Career Start Year 1987
Number of shared co-authors 12

Collaborators

Friedrich St??lzel
University Hospital TU Dresden
Co-authored papers 52
Wolfgang E Berdel
University Hospital Munster
Co-authored papers 38
Leo Ruhnke
University Hospital Dresden
Co-authored papers 11
Heidi Altmann
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 9
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 6
Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
Co-authored papers 5
Michael Heuser
Hannover Medical School
Co-authored papers 5
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Co-authored papers 5
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Co-authored papers 4
Felicitas Thol
Hannover Medical School
Co-authored papers 4
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 3
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 3
Jorge Cortes
Georgia Cancer Center
Co-authored papers 3
Dietger Niederwieser
University of Leipzig
Co-authored papers 3
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 3
Lionel Ad??s
Assistance Publique des Hopitaux de Paris (AP-HP)
Co-authored papers 2
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Co-authored papers 2
Konstantin Strauch
German Research Center for Environmental Health, Institute of Genetic Epidemiology
Co-authored papers 2
Marlise R Luskin
Dana-Farber Cancer Institute
Co-authored papers 2
Kenneth C Anderson
Dana Farber Cancer Institute
Co-authored papers 2
Daniel H??bschmann
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Co-authored papers 2
Thorsten Braun
Centre Hospitalier Universitaire Hopital Avicenne
Co-authored papers 2
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 2
Sagar Lonial
Co-authored papers 2
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Co-authored papers 2
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Co-authored papers 2
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 2
Ashok Kumar Jayavelu
German Cancer Research Center (DKFZ)
Co-authored papers 2
Cyrus Khandanpour
University Hospital of Muenster
Co-authored papers 2
Desiree Kunadt
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 1
Release 1.2